Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

[CMP] [cell line] [SIDM00289] Childhood B Acute Lymphoblastic Leukemia

ABSTRACT:

SUBMITTER:

PROVIDER: S-CMO1075 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Proteogenomics of High hyperdiploid childhood acute lymphoblastic leukemia

Project description:Proteogenomic analysis and genomic profiling, RNA-sequencing, and mass spectrometry-based analysis of High hyperdiploid childhood acute lymphoblastic leukemia.

2019-02-25 | PXD010175 | Pride

Deregulated WNT signaling in childhood T-cell acute lymphoblastic leukemia.

Project description: Not available

| S-EPMC3972698 | biostudies-literature

Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia.

Project description: Not available

| S-EPMC3693942 | biostudies-literature

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.

Project description: Not available

| S-EPMC4567699 | biostudies-literature

Genomic characterization of childhood acute lymphoblastic leukemia.

Project description: Not available

| S-EPMC3848419 | biostudies-literature

Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia.

Project description: Not available

| S-EPMC6853288 | biostudies-literature

Investigating CD99 Expression in Leukemia Propagating Cells in Childhood T Cell Acute Lymphoblastic Leukemia.

Project description: Not available

| S-EPMC5072597 | biostudies-literature

Proteogenomics of High hyperdiploid childhood acute lymphoblastic leukemia

Project description:Proteogenomic analysis and genomic profiling, RNA-sequencing, and mass spectrometry-based analysis of High hyperdiploid childhood acute lymphoblastic leukemia.

2020-01-29 | MSV000084862 | MassIVE

Proteomics analysis of childhood acute lymphoblastic leukemia cell lines reveals novel drug vulnerabilities

Project description:Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and it has a 5-year survival rate of 85% for European children. But for subsets of patients who fail to respond to standard of care chemotherapeutics, treatment options are limited, and clinical prognosis is poor. To establish a platform and methodology to better characterize ALL subtypes and identify their pharmacologic vulnerabilities, we assembled a biobank of 49 readily available childhood ALL cell lines representing diverse immunotypes and genetic profiles. Using these cell lines, we performed comprehensive multi-omic analyses, providing proteomic, transcriptomic and pharmacoproteomic characterization of childhood ALL. We used this resource to characterize the functional impact of genetic fusions and cellular differentiation states on the proteome. Additionally, we identified a novel drug vulnerability in one of the ALL subtypes. Our results are provided as an interactive online data portal with navigable proteomics, transcriptomics, and drug sensitivity profiles.

2022-03-26 | PXD023662 | Pride

Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia.

Project description: Not available

| S-EPMC7686545 | biostudies-literature